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Small cell lung cancer (SCLC) represents approximately 13%
of all lung cancer diagnoses and the incidence has reduced
over the last 20 years. Treatment of SCLC remains challeng-
ing because of its rapid growth, early dissemination and
development of drug resistance during the course of the
disease.
Chemotherapy remains the cornerstone of treatment for
limited (LD) and extensive disease (ED), with concurrent
chemotherapy and radical thoracic radiotherapy representing
the best treatment option for ﬁt patients with LD. Platinum-
based chemotherapy is the treatment of choice in ﬁt patients
with good organ function, and the radiosensitizing effect of
cisplatin is critically important for concurrent RTCT in LD.
The standard of care in good PS (0–1 and sometimes 2) stage
I–III SCLC is early concurrent RTCT followed by PCI with the
best survival results being achievedwith twice-daily radiation.
As a result of the implementation of early concurrent RTCT,
the 5-year survival of stage I–III SCLC patients has increased
from 15% with sequential RTCT to 25–30% with early concur-
rent RTCT.
A strategy to improve on the results of concurrent RTCT
is to test the delivery of higher doses of radiation delivered
once a day against the twice a-daily Turrisi regimen (45Gy in
30 fractions). However, the question of dose has to be weighed
against the importance of the treatment time delivery, as it is
unclearwhether thebetter results in the twice-daily armof the
Turrsisi study are explained by the increase in the biological
effective dose of radiation or by the use of altered fractionation
leading to a shorter overall treatment time. Furthermore, the
analysis of four randomized trials suggested that time from
start of any treatment to completion of radiotherapy (SER)may
be a key variable in predicting outcome.
The omission of elective nodal irradiation (ENI) is another
strategy to improve on the current results of CTRT as it reduces
the exposure of normal tissue to high doses of radiation and
can potentially allow dose escalation in order to improve local
control. Three small phase II studies have reported on the use
of RTCT without ENI with rates of isolated out-of-ﬁeld nodal
relapse in 5% (n=38) and 11% (n=27) of patients using CT-
based radiotherapy planning; and 3% of patients (n=60) using
FDG-PETCT based radiotherapy planning.
Prophylactic cranial irradiation has been shown to reduce
the incidence of brain metastases and prolong survival for
both LD and ED without negative impact on quality of life
(QOL) and cognitive function. The standard dose of PCI (25Gy
in 10 fractions) therefore remains the standard of care in stage
I–III SCLC patients. Ongoing trials will shed some light on
the impact of thoracic radiotherapy on QOL, symptom control
and survival in ED SCLC patients who beneﬁted from ﬁrst-line
chemotherapy.
1507-1367/$ – see front matter © 2013 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer Centre.
http://dx.doi.org/10.1016/j.rpor.2013.04.006
